Zimmer Biomet stock leans on its core joint repair business.

Zimmer Biomet Holdings (ISIN US98956P1021) remains a large-cap U.S. medtech company with a core business built around orthopedic reconstruction, sports medicine, and surgical technology. The shares trade on the NYSE under ZBH.

Business model first

The company sells implants, instruments, and related systems used in hip and knee procedures, along with products that support trauma and extremities care. That mix makes procedure volumes and hospital purchasing trends central to the investment case.

Zimmer Biomet also operates in a sector where replacement cycles, surgeon preference, and product launches can influence revenue mix over time. For U.S. investors, the relevant frame is a mature healthcare supplier rather than a high-growth software story.

What matters now

The shares are best read through the lens of orthopedic procedure recovery, pricing discipline, and execution across the company's surgical portfolio. Analysts typically watch those operating drivers closely when evaluating medtech names with recurring hospital exposure.

Strategically, Zimmer Biomet's position in large joint reconstruction gives it a steady but competitive foothold in a market that depends on both demographics and care volume. That keeps the business tied to incremental gains in installed base and product adoption.

Core product set

Representative products include knee and hip replacement systems, trauma devices, and surgical robotics-adjacent tools within the broader orthopedic workflow. Those lines define the company's commercial identity more clearly than any short-term trading move.

Stock context

Zimmer Biomet shares are listed on the New York Stock Exchange under ZBH. As of July 8, 2026, the stock price was not included in the available source set.